A carregar...
Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-free days at da...
Na minha lista:
| Publicado no: | Crit Care Explor |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7808529/ https://ncbi.nlm.nih.gov/pubmed/33490955 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCE.0000000000000327 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|